Panel discussion

Domenic A. Sica, MD
Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Virginia Commonwealth University Health System, Richmond, VA

Gary Francis, MD
Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH

W.H. Wilson Tang, MD
Section of Heart Failure and Cardiac Transplantation Medicine, Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH

Steven R. Goldsmith, MD
Division of Cardiology, Hennepin County Medical Center, Minneapolis, MN

Mihai Gheorghiade, MD
Divison of Cardiology, Northwestern University Feinberg School of Medicine, Chicago, IL

Dr. Sica reported that he has no financial relationships that pose a potential conflict of interest with this article.

Dr. Francis reported that he is a consultant to and has done teaching and speaking for the Amgen, Merck, Novartis, and Otsuka corporations.

Dr. Tang reported that he has served as a consultant to the FlowMedica, Medtronic, Neurocrine Biosciences, and Otsuka corporations.

Dr. Goldsmith reported that he is a consultant to the Astellas corporation and is on the speakers’ bureaus of the Astellas and GlaxoSmithKline corporations.

Dr. Gheorghiade reported that he is a consultant to the GlaxoSmithKline, Medtronic, Otsuka, PDL BioPharma, Pfizer, and Sigma Tau corporations.

Domenic A. Sica, MD
Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Virginia Commonwealth University Health System, Richmond, VA

Gary Francis, MD
Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH

W.H. Wilson Tang, MD
Section of Heart Failure and Cardiac Transplantation Medicine, Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH

Steven R. Goldsmith, MD
Division of Cardiology, Hennepin County Medical Center, Minneapolis, MN

Mihai Gheorghiade, MD
Divison of Cardiology, Northwestern University Feinberg School of Medicine, Chicago, IL

Dr. Sica reported that he has no financial relationships that pose a potential conflict of interest with this article.

Dr. Francis reported that he is a consultant to and has done teaching and speaking for the Amgen, Merck, Novartis, and Otsuka corporations.

Dr. Tang reported that he has served as a consultant to the FlowMedica, Medtronic, Neurocrine Biosciences, and Otsuka corporations.

Dr. Goldsmith reported that he is a consultant to the Astellas corporation and is on the speakers’ bureaus of the Astellas and GlaxoSmithKline corporations.

Dr. Gheorghiade reported that he is a consultant to the GlaxoSmithKline, Medtronic, Otsuka, PDL BioPharma, Pfizer, and Sigma Tau corporations.

Domenic A. Sica, MD
Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Virginia Commonwealth University Health System, Richmond, VA

Gary Francis, MD
Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH

W.H. Wilson Tang, MD
Section of Heart Failure and Cardiac Transplantation Medicine, Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH

Steven R. Goldsmith, MD
Division of Cardiology, Hennepin County Medical Center, Minneapolis, MN

Mihai Gheorghiade, MD
Divison of Cardiology, Northwestern University Feinberg School of Medicine, Chicago, IL

Dr. Sica reported that he has no financial relationships that pose a potential conflict of interest with this article.

Dr. Francis reported that he is a consultant to and has done teaching and speaking for the Amgen, Merck, Novartis, and Otsuka corporations.

Dr. Tang reported that he has served as a consultant to the FlowMedica, Medtronic, Neurocrine Biosciences, and Otsuka corporations.

Dr. Goldsmith reported that he is a consultant to the Astellas corporation and is on the speakers’ bureaus of the Astellas and GlaxoSmithKline corporations.

Dr. Gheorghiade reported that he is a consultant to the GlaxoSmithKline, Medtronic, Otsuka, PDL BioPharma, Pfizer, and Sigma Tau corporations.